Franz H. Messerli MDProfessor of Medicine, Division of Cardiology, Mount Sinai Health Medical Center, Icahn School of Medicine, New York, New York
Franz H. Messerli, MD, is an expert in hypertensive cardio-vascular disease and preventive cardiology. He presently is Professor of Medicine at Mount Sinai Health Medical Center, Icahn School of Medicine in the Division of Cardiology. After earning his medical degree from the University of Bern Medical School in Switzerland, Dr. Messerli completed his post-graduate training in internal medicine and cardiology at the University of Bern. This was followed by a research fellowship at the Clinical Research Institute and the Hotel Dieu Hospital in Montreal, Canada.
Before coming to New York, Dr. Messerli was for many years director of clinical research at the Ochsner Clinical Foundation and Clinical Professor of Medicine at Tulane University School of Medicine in New Orleans. He served on the Cardiorenal Advisory Committee of the Food and Drug Administration (FDA) and is or has been a member of the editorial board of Circulation, Journal of the American College of Cardiology, European Heart Journal, American Journal of Cardiology, Journal of Hypertension, etc. On his CV there are more than 800 publications and he has been first author on several papers in the New England Journal of Medicine, Lancet, Jama, Annals of Internal Medicine etc. As principal investigator he participated in numerous clinical trials. For his scientific achievements Dr. Messerli has received several awards among them recently a honoris causa doctorate from the Jagiellonian University in Krakow, Poland.
Franz H. Messerli, MD currently has consultant or advisory relationships with the following companies: Daiichi-Sankyo, Pfizer, Abbott, Servier, Medtronic, WebMD, IPCA
Recent Contributions to PracticeUpdate:
- Contributions of Systolic and Diastolic Blood Pressures to Cardiovascular Outcomes in the ALLHAT Study
- Improved Safety of ARBs vs ACE Inhibitors as First-Line Treatment
- Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring
- Blood Pressure Lowering in Type 2 Diabetes